Standard triple therapy is falling short for H. pylori in Saudi Arabia -- quadruple regimens deliver much better cure rates.
Fahd Almalki, Abdullah D. Alotaibi, Majed Almaghrabi, et al.
In a real-world study of 690 Saudi patients treated for Helicobacter pylori, concomitant quadruple therapy and levofloxacin-based regimens achieved eradication rates above 87%, far outperforming standard triple therapy's roughly 74% success. No single patient or treatment factor independently predicted failure after statistical adjustment. The authors recommend moving away from standard triple therapy toward quadruple or levofloxacin-based first-line regimens, alongside better local resistance surveillance.
- The question: Which regimen actually cures the infection: standard triple therapy, or newer alternatives?
- The study: A real-world, multicenter study followed 690 Saudi patients treated for H. pylori.
- The finding: Standard triple therapy eradicated the infection in only about 74% of patients. Concomitant quadruple therapy and levofloxacin-based regimens did better than 87%.
- The nuance: No single patient or treatment factor independently predicted failure. Local resistance surveillance is still needed.
Takeaway: move away from standard triple therapy toward quadruple or levofloxacin-based first-line regimens.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.